Tags

Type your tag names separated by a space and hit enter

A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris.
Br J Dermatol. 1997 Apr; 136(4):575-7.BJ

Abstract

In a double-blind, parallel group study we compared fluconazole 150 mg once weekly with griseofulvin 500 mg once daily for 4-6 weeks in the treatment of tinea corporis or tinea cruris. Eighty-four of 114 patients (74%) (39% after 3 weeks) were clinically cured in the fluconazole group compared with 72 of 116 (62%) (39% after 3 weeks) in the griseofulvin group (P = 0.06). In the fluconazole group 78% were mycological cured compared with 80% in the griseofulvin group. In the fluconazole group nine patients (7.5%) had treatment related adverse events and in the griseofulvin group 15 patients (12.5%) had adverse events. Fluconazole 150 mg once weekly for 6 weeks is both clinically and mycologically effective in the treatment of tinea corporis and tinea cruris and few side-effects were reported.

Authors+Show Affiliations

Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

9155961

Citation

Faergemann, J, et al. "A Multicentre (double-blind) Comparative Study to Assess the Safety and Efficacy of Fluconazole and Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris." The British Journal of Dermatology, vol. 136, no. 4, 1997, pp. 575-7.
Faergemann J, Mörk NJ, Haglund A, et al. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol. 1997;136(4):575-7.
Faergemann, J., Mörk, N. J., Haglund, A., & Odegård, T. (1997). A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. The British Journal of Dermatology, 136(4), 575-7.
Faergemann J, et al. A Multicentre (double-blind) Comparative Study to Assess the Safety and Efficacy of Fluconazole and Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris. Br J Dermatol. 1997;136(4):575-7. PubMed PMID: 9155961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. AU - Faergemann,J, AU - Mörk,N J, AU - Haglund,A, AU - Odegård,T, PY - 1997/4/1/pubmed PY - 1997/4/1/medline PY - 1997/4/1/entrez SP - 575 EP - 7 JF - The British journal of dermatology JO - Br J Dermatol VL - 136 IS - 4 N2 - In a double-blind, parallel group study we compared fluconazole 150 mg once weekly with griseofulvin 500 mg once daily for 4-6 weeks in the treatment of tinea corporis or tinea cruris. Eighty-four of 114 patients (74%) (39% after 3 weeks) were clinically cured in the fluconazole group compared with 72 of 116 (62%) (39% after 3 weeks) in the griseofulvin group (P = 0.06). In the fluconazole group 78% were mycological cured compared with 80% in the griseofulvin group. In the fluconazole group nine patients (7.5%) had treatment related adverse events and in the griseofulvin group 15 patients (12.5%) had adverse events. Fluconazole 150 mg once weekly for 6 weeks is both clinically and mycologically effective in the treatment of tinea corporis and tinea cruris and few side-effects were reported. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/9155961/A_multicentre__double_blind__comparative_study_to_assess_the_safety_and_efficacy_of_fluconazole_and_griseofulvin_in_the_treatment_of_tinea_corporis_and_tinea_cruris_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0007-0963&date=1997&volume=136&issue=4&spage=575 DB - PRIME DP - Unbound Medicine ER -